ArticleAnnals of clinical microbiology and antimicrobials2017
The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia.
Article in Annals of clinical microbiology and antimicrobials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Trial
- Cross-sectoral antimicrobial resistance patterns ofVeterinary world · 2026Article
- Molecular Detection of Extended-Spectrum Beta-Lactamase (ESBL) Genes inInternational journal of food science · 2026Article
- Retrospective study on antibiotic resistance profiles of uropathogenicFrontiers in microbiology · 2026Article
- Epidemiology and Antimicrobial Resistance of Uropathogens in a Tertiary Care Center in Riyadh, Saudi Arabia: A One-Year Retrospective Analysis.Pathogens (Basel, Switzerland) · 2025Article
- Clinical impacts and management of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a narrative review.Childhood kidney diseases · 2025Review
- Extended spectrum beta-lactamase producing Escherichia coli encoding aminoglycoside and fluoroquinolone resistant genes in urinary tract infection patients in a tertiary hospital in Nigeria.BMC infectious diseases · 2025Article
- Antimicrobial resistance and beta-lactamase gene distribution among clinical isolates: a two-year cohort study.Scientific reports · 2025Article
- Antimicrobial Resistance Associated with Mass Gatherings: A Systematic Review.Tropical medicine and infectious disease · 2024Review
- Prevalence of carbapenem-resistantSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Point Prevalence Survey of Antimicrobial Use and Resistance during the COVID-19 Era among Hospitals in Saudi Arabia and the Implications.Antibiotics (Basel, Switzerland) · 2023Article
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2023Review
- Uncovering the Important Genetic Factors for Growth during Cefotaxime-Gentamicin Combination Treatment inAntibiotics (Basel, Switzerland) · 2023Article
- Epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli at the human-animal-environment interface in a farming community of central Uganda.PLOS global public health · 2023Article
- Phenotypic Characterization and Antibiograms of Extended-Spectrum Beta-Lactamase-ProducingInfection and drug resistance · 2023Article
- Transmission of Antimicrobial Resistant Bacteria at the Hajj: A Scoping Review.International journal of environmental research and public health · 2022Article
- Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL ProducingHospital pharmacy · 2022Article
- Genome sequencing data of extended-spectrum beta-lactamase-producingData in brief · 2022Article
- Outbreak of drug resistanceIranian journal of microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe infection and prevalence of extended-spectrum β-lactamases (ESBLs) is a worldwide problem, and the presence of ESBLs varies between countries. In this study, we investigated the occurrence of plasmid-mediated ESBL/AmpC/carbapenemase/aminoglycoside resistance gene expression in Escherichia coli using phenotypic and genotypic techniques.
methodsA total of 58 E. coli isolates were collected from hospitals in the city of Makkah and screened for the production of ESBL/AmpC/carbapenemase/aminoglycoside resistance genes. All samples were subjected to phenotypic and genotypic analyses. The antibiotic susceptibility of the E. coli isolates was determined using the Vitek-2 system and the minimum inhibitory concentration (MIC) assay. Antimicrobial agents tested using the Vitek 2 system and MIC assay included the expanded-spectrum (or third-generation) cephalosporins (e.g., cefoxitin, cefepime, aztreonam, cefotaxime, ceftriaxone, and ceftazidime) and carbapenems (meropenem and imipenem). Reported positive isolates were investigated using genotyping technology (oligonucleotide microarray-based assay and PCR). The genotyping investigation was focused on ESBL variants and the AmpC, carbapenemase and aminoglycoside resistance genes. E. coli was phylogenetically grouped, and the clonality of the isolates was studied using multilocus sequence typing (MLST).
resultsOur E. coli isolates exhibited different levels of resistance to ESBL drugs, including ampicillin (96.61%), cefoxitin (15.25%), ciprofloxacin (79.66%), cefepime (75.58%), aztreonam (89.83%), cefotaxime (76.27%), ceftazidime (81.36%), meropenem (0%) and imipenem (0%). Furthermore, the distribution of ESBL-producing E. coli was consistent with the data obtained using an oligonucleotide microarray-based assay and PCR genotyping against genes associated with β-lactam resistance. ST131 was the dominant sequence type lineage of the isolates and was the most uropathogenic E. coli lineage. The E. coli isolates also carried aminoglycoside resistance genes.
conclusionsThe evolution and prevalence of ESBL-producing E. coli may be rapidly accelerating in Saudi Arabia due to the high visitation seasons (especially to the city of Makkah). The health authority in Saudi Arabia should monitor the level of drug resistance in all general hospitals to reduce the increasing trend of microbial drug resistance and the impact on patient therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.